MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$13,581K
Free Cash flow
-$10,993K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income (loss)
Increase (decrease) in accounts ...
Financial expenses, net
Others
Negative Cash Flow Breakdown
Increase in accounts receivable-...
Investment in bank deposits
Increase in r&d grant receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
3,777
18,317
-5,504
2,355
Share-based compensation
398
532
732
598
Depreciation
406
404
387
372
Financial expenses, net
-571
-158
-470
-28
Changes in accrued liability for employee rights upon retirement
-64
5
8
4
Changes in deferred income tax asset
71
71
163
59
Gain on amounts funded in respect of employee rights upon retirement
-
-
2
12
Loss (gain) on sale of fixed assets
-
-
0
-
Gain on conversions of convertible notes
-
-
0
-
Amortization of debt issuance costs and debt discount
-
-
0
-
Decrease in contracts liability
-
-
0
-
Increase in accounts receivable-trade and other assets
15,034
-6,408
-5,878
4,849
Changes in operating lease right of use assets, net
-40
-55
-47
24
Decrease (increase) in inventories
1,818
4,745
4,474
124
Increase in r&d grant receivable
2,100
-
-
-
Increase (decrease) in accounts payable and accruals
3,353
820
4,325
-2,139
Net cash provided by (used in) operating activities
-10,400
22,025
2,030
-3,732
Investment in bank deposits
3,000
5,000
5,000
-
Short-term deposit withdrawal
0
10,000
5,000
-
Purchase of property and equipment
593
761
403
498
Proceeds from sale of property and equipment
-
-
0
-
Amounts funded in respect of employee rights upon retirement, net
33
7
7
6
Increase in restricted deposit
9
9
702
-
Net cash provided by (used in) investing activities
-3,635
4,223
-1,112
-504
Payment for convertible notes redemption
-
-
0
-
Proceeds from issuance of common stock under the sales agreement, net
-
-
0
0
Exercise of warrants and options
0
150
146
0
Net cash provided by financing activities
0
150
146
0
Effect of exchange rate changes on cash and cash equivalents
454
-77
-31
-12
Net increase (decrease) in cash and cash equivalents
-13,581
26,321
1,033
-4,248
Balance of cash and cash equivalents at beginning of period
41,001
14,680
13,647
19,760
Balance of cash and cash equivalents at end of period
27,420
41,001
14,680
13,647
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Effect of exchange rate
changes on cash and cash...
$454K
(11450.00%↑ Y/Y)
Net increase
(decrease) in cash and cash...
-$13,581K
(-628.20%↓ Y/Y)
Canceled cashflow
$454K
Net income (loss)
$3,777K
(209.32%↑ Y/Y)
Increase (decrease) in
accounts payable and...
$3,353K
(277.03%↑ Y/Y)
Financial expenses, net
-$571K
(-428.70%↓ Y/Y)
Depreciation
$406K
(-42.49%↓ Y/Y)
Share-based compensation
$398K
(-58.84%↓ Y/Y)
Changes in deferred
income tax asset
$71K
(-39.83%↓ Y/Y)
Changes in operating
lease right of use...
-$40K
(-205.26%↓ Y/Y)
Net cash provided by
(used in) operating...
-$10,400K
(-1.06%↓ Y/Y)
Net cash provided by
(used in) investing...
-$3,635K
(-384.67%↓ Y/Y)
Canceled cashflow
$8,616K
Increase in accounts
receivable-trade and other assets
$15,034K
(117.29%↑ Y/Y)
Investment in bank deposits
$3,000K
Purchase of property and
equipment
$593K
(-19.54%↓ Y/Y)
Amounts funded in
respect of employee...
$33K
(153.85%↑ Y/Y)
Increase in restricted
deposit
$9K
Increase in r&d grant
receivable
$2,100K
Decrease (increase) in
inventories
$1,818K
(1723.21%↑ Y/Y)
Changes in accrued
liability for employee...
-$64K
(-740.00%↓ Y/Y)
Buy us a coffee
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)